Neuroptix Corporation

Management

Board of Directors

Gunnar Weikert, Chairman of the Board

Gunnar is Chairman, CEO and Founder of Inventages. Before founding Inventages, He has more than 10 years of experience in the pharmaceutical industry. Prior to founding inventages, he was a senior vice president and global head for life science deals at Bayer AG. While at Bayer, he oversaw venture investments in technology companies and collaborations representing some of the biggest deals between big-pharma and biotechnology in the late 1990's. Gunnar holds an MD, a PhD in the field of metabolism from University of Düsseldorf, and an MBA.

Dr. Richard D. Gill

Dr. Gill has 40 years of strategic management, research, and technology commercialization experience in the life sciences industry. As the Launchpad Venture Group P&CEO of TruTouch, in raising $9.2M of $13.5M in order to develop & commercialize the TT2500 & TTAS6000 & bring the 7 year old "Alcohol & Biometric" Company back to the Workplace market in less than 4 years. As President and Chief Executive Officer of ProNAi Therapeutics, the Kalamazoo, MI, based DNAi Drug Development Company for which he & his team raised $11.5M of $13M invested in achieving an IND APPROVED lead drug product PNT2258, in less than 2 year from the pre IND briefing meeting with the FDA, & previously as President and Chef Executive Officer of Signet Laboratories the Dedham, MA, based Evidence Based Medicine company, for which he led a successful M&A strategy – sold to Covance, and prior to that Dr. Gill was the President and Chief Executive Officer of AnVil, the Burlington, MA, based preeminent commercialization partner to the life sciences industry focused on in silico drug discovery and drug development solutions. Prior to AnVil Dr.Gill served as President and Chief Executive Officer of ActiveCyte, Newton, MA, which provided an enterprise wide solution for pharmaceutical intellectual property licensing, & was sold to Wolter's Kluwer. Dr. Gill served as President and Chief Operating Officer of Genome Therapeutics Corp; now Oscient Pharmaceuticals (NASDAQ: GENE now OSCI), a Waltham, MA, genomics company, which focuses on the commercialization of genomics-based drug discovery. He had overall operational and strategic management responsibilities and led the company's successful follow on financing efforts raising $55M. Prior to this Dr. Gill served as General Manager and Senior Vice President of BTG International, Inc., a subsidiary of BTG plc (LSE: BGC), a global leader in the patenting, marketing, and commercialization of intellectual property rights. He led the global biosciences sector of this $1.5 billion company that commercializes technology via acquisition and licensing collaborations with pharmaceutical, biotechnology, and physical sciences companies. Dr. Gill helped lead the management buyout of British Technology Group plc from the British government, the firm's expansion into international markets, and its subsequent initial public offering. Earlier, he held positions of increasing responsibility in research and general management with Unilever plc. in the United Kingdom. Dr. Gill holds a Ph.D. in Endocrinology and a B.Sc. with honors in Physiology and Biochemistry from Reading University, UK.


Christine de los Reyes

Dr. Christine de los Reyes is Vice President of Business Development & Strategic Planning at Alopexx Enterprises, a healthcare investment and development firm based in Concord, MA.  She has over twenty-six years of pharmaceutical experience and most recently was founder and Managing Director of BiotechPartnering Solutions, a business development consulting firm that advises life science companies on partnering strategy, searches for potential partners, coordinates technical evaluation and due diligence, deal structure and transaction negotiation. She has also been on the advisory board of the Neurotechnology Industry Organization, a non-profit trade association that represents companies involved in neuroscience, academic neuroscience research centers and brain-illness advocacy groups. Previously she was Executive Director of Licensing & Development at Pfizer, with a focus on in-licensing in several therapeutic areas including neuroscience, infectious diseases, immunology, dermatology, and ophthalmology. Dr. de los Reyes began her career as Assistant Professor of Pharmacology at the University of Texas. From there she became Director of Clinical Research at Mt. Sinai Medical Center in New York. She earned her Doctorate in Clinical Pharmacy from the University of Texas, a Master’s in Business Administration from St. Joseph’s University, and a Bachelor of Science in Pharmacy from Wayne State University.